Genetic Modifiers of Liver Injury in Hereditary Liver Disease

ABSTRACT

The genetic background of patients with liver diseases modulates hepatic injury, with some individuals being predisposed to better defenses and regenerative capacity. In this review, we focus our description of this phenomenon on inherited disorders affecting the liver, with a particular emphasis on Wilson disease (WD), genetic hemochromatosis, and α-1 anti-trypsin disease (A1-AT). Wide variations in the clinical phenotype of WD may in part be related to the mutations of the ATP7B genotype, though modifier genes and environmental factors also likely play an important role. There is also a significant variability in the expression of iron overload in patients with genetic hemochromatosis that are homozygous for the C282Y mutation. Homozygosity for the A1-ATZ mutation is generally required for the development of liver disease in A1-AT although there is increasing evidence for modifier effects from a heterozygous genotype in other liver diseases.

KEYWORDS

Alpha-1 antitrypsin deficiency - cystic fibrosis - hereditary hemochromatosis - hereditary liver disease - modifier genes - Wilson disease

REFERENCES

• 1 Ala A, Walker A P, Ashkan K, Dooley J S, Schilsky M L. Wilson's disease.  Lancet. 2007;  369 (9559) 397-408
• 2 Ferenci P, Członkowska A, Merle U et al.. Late-onset Wilson's disease.  Gastroenterology. 2007;  132 (4) 1294-1298
• 3 Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis.  Hepatology. 2005;  41 (3) 668-670
• 4 Schilsky M L, Ala A. Genetic testing for Wilson disease: availability and utility.  Curr Gastroenterol Rep. 2010;  12 (1) 57-61
• 5 Cox D W, Prat L, Walshe J M, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry.  Hum Mutat. 2005;  26 (3) 280
• 6 Butler P, McIntyre N, Mistry P K. Molecular diagnosis of Wilson disease.  Mol Genet Metab. 2001;  72 (3) 223-230
• 7 Forbes J R, Cox D W. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins.  Hum Mol Genet. 2000;  9 (13) 1927-1935
• 8 Stapelbroek J M, Bollen C W, van Amstel J K et al.. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis.  J Hepatol. 2004;  41 (5) 758-763
• 9 Gromadzka G, Schmidt H H, Genschel J et al.. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease.  Mov Disord. 2006;  21 (2) 245-248
• 10 Tsivkovskii R, Efremov R G, Lutsenko S. The role of the invariant His-1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B.  J Biol Chem. 2003;  278 (15) 13302-13308
• 11 Sugeno H, Takebayashi Y, Higashimoto M et al.. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma.  Anticancer Res. 2004;  24 (2C) 1045-1048
• 12 Wan L, Tsai C H, Hsu C M et al.. Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B.  Hepatology. 2010;  52 (5) 1662-1670
• 13 Sternlieb I, Twedt D C, Johnson G F et al.. Inherited copper toxicity of the liver in Bedlington terriers.  Proc R Soc Med. 1977;  70 (Suppl 3) 8-9
• 14 Tao T Y, Liu F, Klomp L, Wijmenga C, Gitlin J D. The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein.  J Biol Chem. 2003;  278 (43) 41593-41596
• 15 Weiss K H, Lozoya J C, Tuma S et al.. Copper-induced translocation of the Wilson disease protein ATP7B independent of Murr1/COMMD1 and Rab7.  Am J Pathol. 2008;  173 (6) 1783-1794
• 16 Miyayama T, Hiraoka D, Kawaji F, Nakamura E, Suzuki N, Ogra Y. Roles of COMM-domain-containing 1 in stability and recruitment of the copper-transporting ATPase in a mouse hepatoma cell line.  Biochem J. 2010;  429 (1) 53-61
• 17 Markiewicz-Kijewska M, Szymczak M, Ismail H et al.. Liver transplantation for fulminant Wilson's disease in children.  Ann Transplant. 2008;  13 (2) 28-31
• 18 Korman J D, Volenberg I, Balko J Pediatric and Adult Acute Liver Failure Study Groups et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests.  Hepatology. 2008;  48 (4) 1167-1174
• 19 Joseph B, Kapoor S, Schilsky M L, Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model.  Hepatology. 2009;  49 (5) 1616-1624
• 20 Kasai N, Miyoshi I, Osanai T, Yamashita T, Kamimura E, Yoshida M C. Effects of sex hormones on fulminant hepatitis in LEC rats: a model of Wilson's disease.  Lab Anim Sci. 1992;  42 (4) 363-368
• 21 Njajou O T, Houwing-Duistermaat J J, Osborne R H et al.. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism.  Eur J Hum Genet. 2003;  11 (3) 225-231
• 22 Adams P, Barton J C, McLaren G D et al.. Screening for iron overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) Study.  Can J Gastroenterol. 2009;  23 (11) 769-772
• 23 Qi L, Meigs J, Manson J E et al.. HFE genetic variability, body iron stores, and the risk of type 2 diabetes in U.S. women.  Diabetes. 2005;  54 (12) 3567-3572
• 24 Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients.  Ann N Y Acad Sci. 1988;  526 245-257
• 25 Adams P C, Reboussin D M, Barton J C Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators et al. Hemochromatosis and iron-overload screening in a racially diverse population.  N Engl J Med. 2005;  352 (17) 1769-1778
• 26 Beutler E, Felitti V J, Koziol J A, Ho N J, Gelbart T. Penetrance of 845G—> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.  Lancet. 2002;  359 (9302) 211-218
• 27 Olynyk J K, Cullen D J, Aquilia S, Rossi E, Summerville L, Powell L W. A population-based study of the clinical expression of the hemochromatosis gene.  N Engl J Med. 1999;  341 (10) 718-724
• 28 Phatak P D, Ryan D H, Cappuccio J et al.. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients.  Blood Cells Mol Dis. 2002;  29 (1) 41-47
• 29 Barton J C, Leiendecker-Foster C, Reboussin D M, Adams P C, Acton R T, Eckfeldt J H. Hemochromatosis and Iron Overload Screening Study Research Investigators . Relationships of serum free thyroxine and erythrocyte measures in euthyroid HFE C282Y homozygotes and control subjects: the HEIRS study.  Int J Lab Hematol. 2010;  32 (3) 282-287
• 30 McLaren C E, Barton J C, Adams P C Hemochromatosis and Iron Overload Study Research Investigators et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults.  Am J Med Sci. 2003;  325 (2) 53-62
• 31 Moirand R, Adams P C, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men.  Ann Intern Med. 1997;  127 (2) 105-110
• 32 Barton J C, Edwards C Q, Bertoli L F, Shroyer T W, Hudson S L. Iron overload in African Americans.  Am J Med. 1995;  99 (6) 616-623
• 33 Barton J C, Acton R T, Lee P L, West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent.  Blood Cells Mol Dis. 2007;  39 (2) 206-211
• 34 Frazer D M, Wilkins S J, Becker E M et al.. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats.  Gastroenterology. 2002;  123 (3) 835-844
• 35 Bolondi G, Garuti C, Corradini E et al.. Altered hepatic BMP signaling pathway in human HFE hemochromatosis.  Blood Cells Mol Dis. 2010;  45 (4) 308-312
• 36 Milet J, Dehais V, Bourgain C et al.. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance.  Am J Hum Genet. 2007;  81 (4) 799-807
• 37 Milet J, Le Gac G, Scotet V et al.. A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study.  Blood Cells Mol Dis. 2010;  44 (1) 34-37
• 38 Pietrangelo A, Caleffi A, Henrion J et al.. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes.  Gastroenterology. 2005;  128 (2) 470-479
• 39 Fink S, Schilsky M L. Inherited metabolic disease of the liver.  Curr Opin Gastroenterol. 2007;  23 (3) 237-243
• 40 Teckman J H. Alpha1-antitrypsin deficiency in childhood.  Semin Liver Dis. 2007;  27 (3) 274-281
• 41 Chappell S, Hadzic N, Stockley R, Guetta-Baranes T, Morgan K, Kalsheker N. A polymorphism of the alpha1-antitrypsin gene represents a risk factor for liver disease.  Hepatology. 2008;  47 (1) 127-132
• 42 Frangolias D D, Ruan J, Wilcox P J et al.. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease.  Am J Respir Cell Mol Biol. 2003;  29 (3 Pt 1) 390-396
• 43 Mahadeva R, Westerbeek R C, Perry D J et al.. Alpha1-antitrypsin deficiency alleles and the Taq-I G—> A allele in cystic fibrosis lung disease.  Eur Respir J. 1998;  11 (4) 873-879
• 44 Pan S, Huang L, McPherson J et al.. Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency.  Hepatology. 2009;  50 (1) 275-281
• 45 Marwick T H, Cooney P T, Kerlin P. Cirrhosis and hepatocellular carcinoma in a patient with heterozygous (MZ) alpha-1-antitrypsin deficiency.  Pathology. 1985;  17 (4) 649-652
• 46 Mencin A, Seki E, Osawa Y et al.. Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis.  Hepatology. 2007;  46 (5) 1443-1452
• 47 Eckman E A, Mallender W D, Szegletes T et al.. In vitro transport of active alpha(1)-antitrypsin to the apical surface of epithelia by targeting the polymeric immunoglobulin receptor.  Am J Respir Cell Mol Biol. 1999;  21 (2) 246-252
• 48 Yoshida A, Ewing C, Wessels M, Lieberman J, Gaidulis L. Molecular abnormality of PI S variant of human alpha1-antitrypsin.  Am J Hum Genet. 1977;  29 (3) 233-239
• 49 Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes.  Am J Med Genet. 2002;  111 (1) 88-95
• 50 Eigenbrodt M L, McCashland T M, Dy R M, Clark J, Galati J. Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease.  Am J Gastroenterol. 1997;  92 (4) 602-607
• 51 Banner B F, Karamitsios N, Smith L, Bonkovsky H L. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C.  Am J Gastroenterol. 1998;  93 (9) 1541-1545
• 52 Thomas R M, Schiano T D, Kueppers F, Black M. Alpha1-antichymotrypsin globules within hepatocytes in patients with chronic hepatitis C and cirrhosis.  Hum Pathol. 2000;  31 (5) 575-577
• 53 Combs C, Brunt E M, Solomon H, Bacon B R, Brantly M, Di Bisceglie A M. Rapid development of hepatic alpha1-antitrypsin globules after liver transplantation for chronic hepatitis C.  Gastroenterology. 1997;  112 (4) 1372-1375
• 54 Knaupp A S, Levina V, Robertson A L, Pearce M C, Bottomley S P. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation.  J Mol Biol. 2010;  396 (2) 375-383
• 55 Erhardt A, Hoffmann A, Hefter H, Häussinger D. HFE gene mutations and iron metabolism in Wilson's disease.  Liver. 2002;  22 (6) 474-478
• 56 Abuzetun J Y, Hazin R, Suker M, Porter J. A rare case of hemochromatosis and Wilson's disease coexisting in the same patient.  J Natl Med Assoc. 2008;  100 (1) 112-114
• 57 Dib N, Valsesia E, Malinge M C, Mauras Y, Misrahi M, Calès P. Late onset of Wilson's disease in a family with genetic haemochromatosis.  Eur J Gastroenterol Hepatol. 2006;  18 (1) 43-47
• 58 Kotalová R, Jirsa M, Vávrová V, Vrábelová-Pouchlá S, Macek Jr M. Wilson disease as a cause of liver injury in cystic fibrosis.  J Cyst Fibros. 2009;  8 (1) 63-65
• 59 Bartlett J R, Friedman K J, Ling S C Gene Modifier Study Group et al. Genetic modifiers of liver disease in cystic fibrosis.  JAMA. 2009;  302 (10) 1076-1083